New data shows JNJ-2113, an investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
- EMEA Innovative Medicine
- New data shows JNJ-2113, an investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
New data shows JNJ-2113, an investigational targeted oral peptide, maintained skin clearance in moderate-to-severe plaque psoriasis through one year
- X (Twitter)
Copy link